Check out our most popular compounded medications! Get Started
Chlorpheniramine Maleate 9 mg/Phenylephrine HCl 21 mg Slow Release Capsules are compounded with Methocel E4M, a controlled-release polymer. This formulation ensures a gradual release of the active ingredients over an extended period, providing sustained therapeutic effects. This reduces the need for frequent dosing and enhances patient compliance.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Bayview Pharmacy is pleased to present our compounded formulation of Chlorpheniramine Maleate 9 mg/Phenylephrine HCl 21 mg Slow Release Capsules. This unique formulation is specifically designed to address a range of allergic and respiratory conditions, such as Allergic Rhinitis, Common Cold, Sinusitis, Hay Fever, and Bronchitis. The capsules are formulated with Methocel E4M, a type of controlled-release polymer, which ensures the gradual release of the encapsulated medication over an extended period of time.
This slow-release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications that require a controlled and prolonged release profile. The combination of Chlorpheniramine Maleate and Phenylephrine HCl in our formulation works synergistically to reduce inflammation, alleviate congestion, and provide relief from the symptoms associated with these conditions.
If you have any questions about this formulation or how it can help manage your condition, please do not hesitate to contact us at Bayview Pharmacy.
Chlorpheniramine Maleate 9 mg/Phenylephrine HCl 21 mg Slow Release Capsules are formulated with Methocel E4M, a controlled-release polymer. This design allows for the gradual release of the encapsulated medication over an extended period, providing sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile.
These capsules may interact with other medications, including those used to treat Allergic Rhinitis, Common Cold, Sinusitis, Hay Fever, and Bronchitis. It is crucial for patients to inform their healthcare provider of all medications they are currently taking, including over-the-counter medications, vitamins, and herbal supplements.
Patients should also be aware of potential drug interactions with other medications, such as monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, and other antihistamines. Interactions with alcohol should also be noted, as this may increase the risk of side effects.
Furthermore, potential interactions with other drugs that may affect the central nervous system, such as sedatives, hypnotics, and narcotics, should be considered. Additionally, potential interactions with other drugs that may affect the cardiovascular system, such as beta-blockers, calcium channel blockers, and diuretics, should be taken into account.
If you have any questions about potential interactions with Chlorpheniramine Maleate 9 mg/Phenylephrine HCl 21 mg Slow Release Capsules, please consult with your healthcare provider.
Chlorpheniramine Maleate 9 mg/Phenylephrine HCl 21 mg Slow Release Capsules are a compounded formulation designed to provide extended relief from symptoms associated with Allergic Rhinitis, Common Cold, Sinusitis, Hay Fever, and Bronchitis. This unique formulation combines the antihistamine properties of Chlorpheniramine Maleate, which works by blocking the action of histamine, and the decongestant properties of Phenylephrine HCl, which works by narrowing the blood vessels in the nasal passages. The result is a reduction in congestion, swelling, and other allergic symptoms.
The capsules are formulated with Methocel E4M, a type of controlled-release polymer. This allows for a gradual release of the active ingredients over an extended period of time, offering sustained therapeutic effects and reduced dosing frequency. This slow release formulation provides relief from symptoms for up to 12 hours, improving patient compliance for medications requiring a controlled and prolonged release profile.
When taking Chlorpheniramine Maleate 9 mg/Phenylephrine HCl 21 mg Slow Release Capsules, it is crucial to adhere to the directions provided by your healthcare provider. The recommended dose is one capsule every 12 hours, which can be taken with or without food. It is advised not to exceed two capsules in a 24-hour period and not to continue the medication for more than 7 days unless directed by your healthcare provider.
Common side effects of Chlorpheniramine Maleate 9 mg/Phenylephrine HCl 21 mg Slow Release Capsules may include drowsiness, dry mouth, headache, and nausea. If you experience any of these side effects, it is important to contact your healthcare provider immediately.
If you have any questions or concerns about Chlorpheniramine Maleate 9 mg/Phenylephrine HCl 21 mg Slow Release Capsules, please do not hesitate to reach out to your healthcare provider or pharmacist for further information and guidance.
These are capsules that contain Chlorpheniramine Maleate and Phenylephrine HCl as active ingredients. They are formulated with Methocel E4M, a type of controlled-release polymer, which allows the medication to be released gradually over an extended period of time.
The controlled-release polymer, Methocel E4M, is designed to release the encapsulated medication gradually over an extended period of time. This offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance for medications requiring a controlled and prolonged release profile.
Slow release capsules offer several benefits. They provide sustained therapeutic effects, reduce the need for frequent dosing, and improve patient compliance, especially for medications that require a controlled and prolonged release profile.
As these capsules are designed to release the medication gradually, they are typically taken less frequently than immediate-release formulations. However, the exact dosing schedule should be determined by your healthcare provider based on your specific medical condition and response to therapy.
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
No, these capsules should not be broken, crushed, or chewed. Doing so can release all of the drug at once, increasing the risk of side effects. The capsule should be swallowed whole.
Common side effects may include dizziness, dry mouth, or sleepiness. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. Serious side effects are rare, but if you experience serious side effects such as fast/irregular heartbeat, mental/mood changes, or difficulty urinating, seek medical attention immediately.
Before starting any new medication, it is important to discuss with your healthcare provider. Some medications may interact with Chlorpheniramine Maleate and Phenylephrine HCl, altering how they work or increasing your risk for serious side effects.
Before taking these capsules, inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding. The safety of these medications during pregnancy or breastfeeding has not been fully established and they should only be used if the potential benefits outweigh the potential risks.
If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call emergency services immediately. Symptoms of overdose may include severe drowsiness, seizures, and fast/irregular heartbeat.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
